{"DataElement":{"publicId":"2753241","version":"2","preferredName":"Preparative Regimen Planned Animal Sources Type","preferredDefinition":"A description of the preparative regimen planned animal source.","longName":"2753239v1.0:2488536v2.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2753239","version":"1","preferredName":"Preparative Regimen Planned Source","preferredDefinition":"The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._To devise, contrive, or formed in design._Where something is available or from where it originates.","longName":"PRP_REG_PLN_SRCE","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2685191","version":"1","preferredName":"Preparative Regimen","preferredDefinition":"The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"C61155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B97F286-866B-5609-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-03","modifiedBy":"ONEDATA","dateModified":"2007-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2685017","version":"1","preferredName":"Planned Source","preferredDefinition":"Planned; devised, contrived, or formed in design.:Source; where something is available.","longName":"C25619:C25683","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Source","conceptCode":"C25683","definition":"Where something is available or from where it originates.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B730520-5888-1AA4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-01","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-01","modifiedBy":"ONEDATA","dateModified":"2007-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E045431-739C-492A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-01","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2488536","version":"2.1","preferredName":"Animal Sources Type","preferredDefinition":"indicates whether horse, rabbit or some other source was used in conjunction with human lymphoid or other cells for the creation of the drug_Something distinguishable as an identifiable class based on common qualities.","longName":"2488536v2.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28C0614F-7AB1-3056-E050-BB89AD4346BB","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","deletedIndicator":"No"},{"value":"Thymoglobulin (rabbit)","valueDescription":"Rabbit Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"5097251","version":"1","preferredName":"Rabbit Anti-Thymocyte Globulin","longName":"5097251","preferredDefinition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.: A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rabbit","conceptCode":"C14264","definition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C0614F-7ABE-3056-E050-BB89AD4346BB","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28C0614F-7AD7-3056-E050-BB89AD4346BB","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","deletedIndicator":"No"},{"value":"ATGAM (horse)","valueDescription":"Horse Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"5097253","version":"1","preferredName":"Horse Anti-Thymocyte Globulin","longName":"5097253","preferredDefinition":"The domestic horse, Equus caballus.: A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Horse","conceptCode":"C14222","definition":"The domestic horse, Equus caballus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C0614F-7B0A-3056-E050-BB89AD4346BB","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28C0614F-7B23-3056-E050-BB89AD4346BB","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","deletedIndicator":"No"},{"value":"Horse","valueDescription":"horse","ValueMeaning":{"publicId":"2580041","version":"1","preferredName":"horse","longName":"2580041","preferredDefinition":"The domestic horse, Equus caballus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Horse","conceptCode":"C14222","definition":"The domestic horse, Equus caballus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-05B6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-22","modifiedBy":"CURTIST","dateModified":"2007-03-29","changeDescription":"03/29/2007 - Updated with NCI Thesaurus definition and concept code.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209435FB-626F-8B2A-E050-BB89AD43399C","beginDate":"2006-06-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Rabbit","valueDescription":"Rabbit","ValueMeaning":{"publicId":"3179728","version":"1","preferredName":"Rabbit","longName":"3179728","preferredDefinition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rabbit","conceptCode":"C14264","definition":"Various members of the family Leporidae, especially those of the genus Sylvilagus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F3BAD1-2BE8-DD20-E040-BB89AD431896","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"209435FB-6279-8B2A-E050-BB89AD43399C","beginDate":"2013-09-06","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"ATG - Fresenius (rabbit)","valueDescription":"Fresenius Biotech Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"5097252","version":"1","preferredName":"Fresenius Biotech Anti-Thymocyte Globulin","longName":"5097252","preferredDefinition":"A German company that researches, develops, and markets biopharmaceuticals for the treatment of severe diseases.: A purified gamma immunoglobulin (IgG) with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fresenius Biotech","conceptCode":"C124044","definition":"A German company that researches, develops, and markets biopharmaceuticals for the treatment of severe diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C0614F-7AE4-3056-E050-BB89AD4346BB","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"44A951B8-B04D-1EA7-E053-F662850ACCF8","beginDate":"2016-01-07","endDate":null,"createdBy":"NYCHM","dateCreated":"2016-12-27","modifiedBy":"ONEDATA","dateModified":"2016-12-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2182571","version":"1","preferredName":"Pharmacologic Substance","preferredDefinition":"A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.","longName":"PHARMACOLOGIC SUBSTANCE","context":"caCORE","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"D727D9B9-FB5E-1E8C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-03","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-03","modifiedBy":"DWARZEL","dateModified":"2004-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2488535","version":"1","preferredName":"Animal Sources Type","preferredDefinition":"No Value Exists:Type; a subdivision of a particular kind of thing.","longName":"C18634:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Animal Sources","conceptCode":"C18634","definition":"Indicates that a product is derived from an animal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16D1B008-533A-4B01-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-22","modifiedBy":"ONEDATA","dateModified":"2006-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"209435FB-6258-8B2A-E050-BB89AD43399C","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"NYCHM","dateModified":"2017-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"Animal:speciesCode","type":"HCT_BRIDG","context":"NHLBI"},{"name":"pre_ted_prep_reg_atg_src","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the source of the pre","type":"Preferred Question Text","description":"Specify the source of the preparative regimen medication:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2753241","type":"BRIDG Mapping Path","description":"PerformedSubstanceAdministration > SubstanceExtractionAdministrationRelationship > PerformedSubstanceExtraction (donor) > Subject > Animal.speciesCode WHERE PerformedSubstanceAdministration > DefinedSubstanceAdministration > DefinedCompositionRelationship > DefinedSubjectActivityGroup.nameCode = \"Perform preparative regimen\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5B6AC0C-3009-A8F1-E040-BB89AD43573C","latestVersionIndicator":"Yes","beginDate":"2013-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-09-06","modifiedBy":"KUMMEROA","dateModified":"2021-02-23","changeDescription":". 2021-2-23 ak OK to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}